A phase I and randomized phase II study of cabozantinib plus docetaxel and prednisone (C+DP) versus docetaxel and prednisone (DP) alone in metastatic castrate-resistant prostate cancer (mCRPC).Munjid Al Harthy, William L. Dahut, Ravi A. Madan et al.|Journal of Clinical Oncology|2019Cited by 3
1631P Results from the quick efficacy seeking trial (QuEST1) arm combining BN-brachyury (BNVax) + bintrafusp alfa (BA) + nogapendekin alfa inbakicept-pmln (N-803) in castration-resistant prostate cancer (CRPC)Jason M. Redman, James L. Gulley, Renee N. Donahue et al.|Annals of Oncology|2024Cited by 3
1412P Immune changes after enzalutamide (Enza) is added to androgen-deprivation therapy (ADT) in first-line metastatic castration-resistant prostate cancer (mCRPC)Ravi A. Madan, James L. Gulley, Renee N. Donahue et al.|Annals of Oncology|2022Cited by 2
Intermittent short course enzalutamide in biochemically recurrent prostate cancer: Analysis of PSA recovery, testosterone levels and tolerabilityMunjid Al Harthy, Ravi A. Madan, Harbhej Singh et al.|Annals of Oncology|2018Cited by 1